Posted On: 12/27/2014 3:06:55 PM
Post# of 30035
Most active companies and those with the most orphan designations (ODNs). see link
http://www.nature.com/bioent/2014/140201/fig_....1_F4.html
(a) Bar graph of 20 companies that received the most ODNs from the US Food and Drug Administration (FDA), 2008–2012. Shown are data from both the FDA and the European Medicines Agency (EMA). AstraZeneca. AstraZeneca + MedImmune; Celgene: Celgene + Abraxis; Eisai: Eisai + Morphotek; Eli Lilly: Eli Lilly + ImClone; GSK: GlaxoSmithKline + Stiefel; J&J: Johnson & Johnson + Janssen + Centocor; Novartis: Novartis + Alcon; Pfizer: Pfizer + Wyeth + Pharmacia + King; Roche: Roche + Genentech; Sanofi: Sanofi + Genzyme; Takeda: Takeda + Millennium; Teva: Teva + Cephalon; Valeant: Valeant + Biovail. (b) Bar graph displaying 20 most active acquirers in our dataset.
http://www.nature.com/bioent/2014/140201/full...014.1.html
http://www.nature.com/bioent/2014/140201/fig_....1_F4.html
(a) Bar graph of 20 companies that received the most ODNs from the US Food and Drug Administration (FDA), 2008–2012. Shown are data from both the FDA and the European Medicines Agency (EMA). AstraZeneca. AstraZeneca + MedImmune; Celgene: Celgene + Abraxis; Eisai: Eisai + Morphotek; Eli Lilly: Eli Lilly + ImClone; GSK: GlaxoSmithKline + Stiefel; J&J: Johnson & Johnson + Janssen + Centocor; Novartis: Novartis + Alcon; Pfizer: Pfizer + Wyeth + Pharmacia + King; Roche: Roche + Genentech; Sanofi: Sanofi + Genzyme; Takeda: Takeda + Millennium; Teva: Teva + Cephalon; Valeant: Valeant + Biovail. (b) Bar graph displaying 20 most active acquirers in our dataset.
http://www.nature.com/bioent/2014/140201/full...014.1.html
(0)
(0)Scroll down for more posts ▼
